Researchers from Virginia Commonwealth University Report Recent Findings in Managed Care (The Inclusion of Economic Endpoints as Outcomes in Clinical Trials Reported to ClinicalTrials.gov)

2020 APR 29 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- Research findings on Managed Care are discussed in a new report. According to news reporting out of Richmond, Virginia, by NewsRx editors, research stated, “As medication expenditures rise, payers are increasingly demanding evidence of economic value for new medications. The 2015 Professional Society for Health Economics and Outcomes Research (ISPOR) Task Force on Cost-Effectiveness Analysis Alongside Clinical Trials noted that clinical trials are increasingly including health care utilization endpoints to address this rising interest in economic information.”

Our news journalists obtained a quote from the research from Virginia Commonwealth University, “To (a) describe the prevalence of economic endpoints in clinical trials submitted to ClinicalTrials.gov and (b) examine associations between trial characteristics and the inclusion of economic endpoints. This retrospective review of ClinicalTrials.gov data extracted the characteristics of clinical trials that were submitted to ClinicalTrials.gov from January 2004 to December 2018; studied a drug and/or biological; and had a recruitment status of not yet recruiting, recruiting, active but not recruiting, or completed. Studies were classified as containing an economic endpoint based on 2 independent evaluations of the inclusion of endpoints relevant to costs, resource utilization, cost-effectiveness, productivity, absenteeism, presenteeism, or unemployment. Descriptive statistics were used to summarize trial characteristics, and chi-square analyses were used to evaluate differences in characteristics between trials with and without economic endpoints. Of the 104,885 trials included in the study, 1,437 (1.37%) included an economic endpoint; among later phase (phase 2/3, 3, 4) trials, 939 (2.54%) included economic endpoints. Compared with studies that did not include economic endpoints, those that did were less often industry funded (48.0% vs. 52.0%, P< 0.001) and were for a high-spend specialty condition (24.1% vs. 27.4%, P< 0.001). The proportion of trials that included economic endpoints increased by a small but significant amount over the time period studied, from 1.2% (2004-2008) to 1.6% (2014-2018; P< 0.001). A small but growing number of clinical trials are including economic endpoints. This finding may reflect continued industry concerns surrounding the cost and logistical challenges of piggybacking economic data collection alongside clinical trials and/or manufacturers’ preferences for modeling for value demonstration.”

According to the news editors, the research concluded: “Future research is needed to better understand barriers to the inclusion of economic endpoints as well as the degree to which incorporating health care resource utilization collected during clinical trials into early economic modeling may reduce payer concerns about model transparency and bias.”

For more information on this research see: The Inclusion of Economic Endpoints as Outcomes in Clinical Trials Reported to ClinicalTrials.gov. Journal of Managed Care & Specialty Pharmacy, 2020;26(4):386-393. Journal of Managed Care & Specialty Pharmacy can be contacted at: Acad Managed Care Pharmacy, 100 N Pitt St, 400, Alexandria, VA 22314-3134, USA.

Our news journalists report that additional information may be obtained by contacting J.A. Patterson, Virginia Commonwealth University, School of Pharmacy, Dept Pharmacotherapy & Outcomes Scrence, 410 N 12TH St, Box 980581, Richmond, VA 23298, United States.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.18553/jmcp.2020.26.4.386. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)